Episode 20 - Pharmacotherapeutic Initiatives

As clinicians recognize the importance of controlling a full spectrum of comorbidities linked to cardiometabolic events, David Calabrese, RPh, MHP, highlights the benefits of new single-agents and explains how these options treat multiple components.

Yehuda Handelsman, MD, FACP, FACE, FNLA, explains that as different formulations with different delivery systems evolve, they offer additional benefits to clinicians and patients.

For example, Dr Handelsman points out that when delivering insulin for the treatment of diabetes, new agents can be administered through a pen option instead of a syringe. Additionally, he explains that many new agents are long-acting, offering more convenience to patients.

Concerned about the differences in cost between older and newer agents, Kenneth L. Schaecher, MD, FACP, CPC, questions Dr Handelsman about the significance of utilizing the pen rather than

the syringe as a delivery option.

Dr Handelsman explains that although the pen option is a more expensive delivery option, the accuracy of the pen has been acknowledged in many settings, including the hospital setting, and has helped improve glycemic goals.